A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated fibroblasts, can help lung cancer cells survive targeted drug therapy by activating multiple survival routes that allow tumors to evade treatment. Results of the study, published in Science Signaling, provide valuable insights into why some cancers are resistant to currently approved therapies.
This article was originally published on MedicalXpress.com

